TGA vs ARTG vs PBAC vs PBS: How Australian Medicine Approval and Subsidy Differ

Last reviewed: 7 October 2026. A medicine can be approved for supply in Australia without being subsidised through the Pharmaceutical Benefits Scheme. It can also receive a positive Pharmaceutical Benefits Advisory Committee recommendation before it appears in the PBS Schedule. The terms TGA, ARTG, PBAC and PBS describe related but different parts of the Australian system.

TGA: the regulator, not a list of subsidised medicines

The Therapeutic Goods Administration is Australia’s national regulator for therapeutic goods. For registered prescription medicines, its work includes assessing evidence about quality, safety and efficacy, maintaining post-market oversight and taking regulatory action when necessary.

“TGA approved” is often used as shorthand, but readers should ask a more precise question: which product, formulation, sponsor, indication and ARTG entry are being discussed? An ingredient name by itself is not an approval record. Nor does an overseas approval automatically establish Australian approval.

The TGA also administers the Poisons Standard, which contains scheduling decisions used in state and territory medicines and poisons laws. Scheduling and market authorisation are different questions. A substance’s schedule can affect how it may be supplied, while ARTG inclusion concerns a specific therapeutic good.

ARTG: the public register for specific therapeutic goods

The Australian Register of Therapeutic Goods is the TGA’s public reference database. The TGA describes it as the register of therapeutic goods that can be legally supplied in Australia. Its records can include the product name, sponsor, active ingredients, dosage form, strength, route, indications and other identifying details.

An ARTG search must be specific. Searching only a broad ingredient or brand family can miss important distinctions between:

• different sponsors or manufacturers;
• different formulations, strengths or routes;
• registered medicines and listed medicines;
• approved indications and unrelated marketing claims;
• a medicine and a similarly named compounded or “research use only” product.

Most therapeutic goods must be included in the ARTG before supply in Australia, but lawful access pathways and exemptions can exist in defined circumstances. Those exceptions do not convert the product into an ARTG-approved medicine and should not be described that way.

PBAC: an evidence and value recommendation

The Pharmaceutical Benefits Advisory Committee is an independent expert committee that advises the Australian Government about PBS listing. In making a recommendation, the PBAC considers the medical condition, clinical effectiveness, safety and cost-effectiveness compared with other treatments.

A PBAC decision is normally narrower than the name of the medicine. It may concern one indication, population, treatment line, prescriber type, combination, strength or restriction. A positive recommendation therefore needs to be read with its exact wording.

PBS: the live subsidy schedule

The Pharmaceutical Benefits Scheme helps subsidise medicines for eligible patients. The PBS Schedule lists the medicines currently available at a government-subsidised price and states the item, form, strength, quantity, repeats and applicable restrictions.

A medicine may be TGA-approved and available privately but not listed on the PBS for that use. It may also be PBS-listed for one indication or patient group but not another. The accurate question is therefore not simply “Is this drug on the PBS?” but:

Is this exact medicine, form and strength PBS-listed today for this indication and patient group, under what authority and restriction?

How the pathway usually fits together

The stages can overlap operationally, and sponsors may use parallel processes, but the public status claims remain distinct. Readers should verify the current record rather than infer one stage from another.

Worked example: Wegovy on 7 October 2026

Wegovy shows why the four labels must stay separate. The medicine is TGA-approved for chronic weight management, and PBAC recommended a restricted PBS listing for people with established cardiovascular disease and obesity. But the official medicine-status record—information current as at 1 October 2026—still says complete documentation was not accepted, listing arrangements and government processes had not commenced, and PBS listing had not occurred.

For the live brand-by-brand position—including Ozempic, Trulicity, Saxenda, Wegovy and Mounjaro—use our GLP-1 medicines in Australia status guide. The source record is the PBS Wegovy medicine-status page.

Five common mistakes

1. “Approved overseas means approved in Australia.” Australian status must be checked in Australian sources.
2. “The ingredient appears in the ARTG, so every product containing it is approved.” ARTG entries apply to specific goods, sponsors, formulations and uses.
3. “PBAC recommended it, so it is on the PBS now.” Additional steps occur before a recommendation becomes a live listing.
4. “It is on the PBS, so all patients receive the subsidy.” Restrictions, authorities, indications and clinical criteria can limit subsidised access.
5. “Not PBS-listed means illegal or unapproved.” PBS status concerns subsidy. A TGA-approved medicine may be supplied privately without PBS subsidy.

A six-step verification method

1. Identify the exact product. Record the brand, active ingredient, form, strength, route and sponsor.
2. Search the ARTG. Confirm that the matching entry exists and read its public details.
3. Check the approved indication. Use current TGA Product Information, not an advertisement or search snippet.
4. Check PBAC status separately. Read the outcome for the relevant meeting, population and requested restriction.
5. Check the live PBS Schedule. Confirm that an item number and restriction are currently present.
6. Date the conclusion. Regulatory, funding and restriction status can change; record when each source was checked.

What “available in Australia” can mean

The word “available” is too vague for accurate health publishing. It might mean that:

• a product has an ARTG entry;
• stock is commercially distributed;
• a medicine can be privately prescribed;
• a patient may qualify under a defined unapproved-goods access pathway;
• the product is PBS-listed for a restricted population; or
• a website is merely willing to ship an unapproved product.

These situations have different legal, clinical and financial meanings. A credible status page should name the exact one.

Frequently asked questions

Does ARTG inclusion mean a medicine is on the PBS?

No. ARTG inclusion concerns regulatory status and supply. PBS listing concerns government subsidy under defined conditions.

Does a positive PBAC recommendation guarantee listing?

No. It is an essential recommendation, but other pricing, documentation, availability and government processes may remain before a PBS listing takes effect.

Can a medicine be approved but not subsidised?

Yes. A TGA-approved medicine can be available privately without a PBS listing for that medicine, indication or patient group.

Is the Poisons Standard the same as the ARTG?

No. The Poisons Standard classifies substances into schedules used by state and territory controls. The ARTG records specific therapeutic goods included for supply, subject to the regulatory framework and any applicable exceptions.

Does “research use only” create an exemption?

No. The TGA states that such disclaimers alone do not change a product’s regulatory status, permit importation or remove advertising and supply obligations.

Official sources

1. TGA: About the Australian Register of Therapeutic Goods
2. TGA: Searching the ARTG
3. TGA: How medicines are regulated
4. TGA: The Poisons Standard
5. PBS: Pharmaceutical Benefits Advisory Committee
6. PBS: PBAC outcomes and post-recommendation steps
7. PBS: About the Pharmaceutical Benefits Scheme
8. PBS Medicine Status